CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on CRVO stock, giving a Buy rating on March 5.

Ram Selvaraju has given his Buy rating due to a combination of factors tied to CervoMed’s lead asset and its clinical trajectory. He views the upcoming AD/PD 2026 presentations as important value inflection points, since new Phase 2b RewinD-LB analyses and biomarker-based patient selection appear to validate neflamapimod’s disease-modifying potential in dementia with Lewy bodies and refine the design of the planned Phase 3 trial.

He also highlights the clearly defined pivotal program, including a global Phase 3 study with a clinically meaningful primary endpoint, Fast Track status, and the possibility of Priority Review that could support market entry around 2029. Combined with sufficient cash to operate into the second half of 2026 and a projected narrowing of losses over time, these elements underpin his conviction in both the clinical and financial upside, supporting a reiterated Buy rating and a $25 twelve‑month price target.

Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Aclaris Therapeutics, and Idorsia Ltd. According to TipRanks, Selvaraju has an average return of 20.7% and a 52.09% success rate on recommended stocks.

In another report released on March 5, Roth MKM also maintained a Buy rating on the stock with a $19.00 price target.